189 related articles for article (PubMed ID: 23444498)
1. 13-valent pneumococcal vaccine: 50 years of age and older.
Prescrire Int; 2013 Feb; 22(135):38. PubMed ID: 23444498
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
[TBL] [Abstract][Full Text] [Related]
3. 7-valent pneumococcal conjugate vaccine: new preparation. Prevents rare invasive infections in infants.
Prescrire Int; 2002 Feb; 11(57):7-10. PubMed ID: 11985376
[TBL] [Abstract][Full Text] [Related]
4. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
[TBL] [Abstract][Full Text] [Related]
5. The future of pneumococcal disease prevention.
Rodgers GL; Klugman KP
Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
[TBL] [Abstract][Full Text] [Related]
6. A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):901-11. PubMed ID: 25186657
[TBL] [Abstract][Full Text] [Related]
7. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
Zangeneh TT; Baracco G; Al-Tawfiq JA
Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
[TBL] [Abstract][Full Text] [Related]
8. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
9. 13-valent pneumococcal conjugate vaccine.
Prescrire Int; 2011 Jan; 20(112):5-7, 9. PubMed ID: 21462782
[TBL] [Abstract][Full Text] [Related]
10. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
11. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
Mitchell R; Trück J; Pollard AJ
Expert Opin Biol Ther; 2013 Oct; 13(10):1451-65. PubMed ID: 23889554
[TBL] [Abstract][Full Text] [Related]
12. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
Lexau CA; Lynfield R; Danila R; Pilishvili T; Facklam R; Farley MM; Harrison LH; Schaffner W; Reingold A; Bennett NM; Hadler J; Cieslak PR; Whitney CG;
JAMA; 2005 Oct; 294(16):2043-51. PubMed ID: 16249418
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
[TBL] [Abstract][Full Text] [Related]
14. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal conjugated vaccine: PHiD-CV.
Dinleyici EC; Yargic ZA
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
[TBL] [Abstract][Full Text] [Related]
16. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
18. Use of pneumococcal polysaccharide vaccines: no simple answers.
French N
J Infect; 2003 Feb; 46(2):78-86. PubMed ID: 12634068
[TBL] [Abstract][Full Text] [Related]
19. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.
Dinleyici EC; Yargic ZA
Expert Rev Vaccines; 2009 Aug; 8(8):977-86. PubMed ID: 19627181
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
